Harnessing AAV tropisms

Bamboo harnesses vector tropisms to develop tissue-targeting gene therapies

Bamboo Therapeutics Inc. is developing adeno-associated viral vector-based gene therapies that preferentially target tissues affected by CNS and neuromuscular disorders. By homing in on specific tissues, Bamboo's gene therapies could minimize off-target toxicities and reduce the amount of virus needed to produce a therapeutic effect.

The newco spun out of gene therapy company Asklepios BioPharmaceutical Inc. last year with an initial focus on BMB-D001, a systemic gene therapy for Duchenne muscular dystrophy designed to produce a functional form of dystrophin specifically in tissues where

Read the full 856 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE